These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26621380)

  • 1. NICE guidance on pembrolizumab for advanced melanoma.
    Watson I; Dominguez PP; Donegan E; Charles Z; Robertson J; Adam EJ
    Lancet Oncol; 2016 Jan; 17(1):21-2. PubMed ID: 26621380
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma.
    Sullivan RJ; Flaherty KT
    Nat Rev Clin Oncol; 2015 Nov; 12(11):625-6. PubMed ID: 26416151
    [No Abstract]   [Full Text] [Related]  

  • 3. Pembrolizumab superior to ipilimumab in melanoma.
    Cancer Discov; 2015 Jun; 5(6):568. PubMed ID: 25895921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab for patients with advanced melanoma.
    Burki TK
    Lancet Oncol; 2015 Jun; 16(6):e264. PubMed ID: 25921425
    [No Abstract]   [Full Text] [Related]  

  • 6. Pembrolizumab for melanoma- safety profile and future trends.
    Daud A; Nandoskar P
    Expert Opin Drug Saf; 2016 Jun; 15(6):727-9. PubMed ID: 27056241
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Hua C; Boussemart L; Mateus C; Routier E; Boutros C; Cazenave H; Viollet R; Thomas M; Roy S; Benannoune N; Tomasic G; Soria JC; Champiat S; Texier M; Lanoy E; Robert C
    JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab for the treatment of melanoma.
    Kumar SS; McNeil CM
    Expert Rev Clin Pharmacol; 2015; 8(5):515-27. PubMed ID: 26146011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subsidised access to new melanoma drugs: in need of further innovation?
    Wonder M; Fisher R
    N Z Med J; 2016 Aug; 129(1440):37-54. PubMed ID: 27538038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
    Sullivan RJ; Flaherty KT
    Clin Cancer Res; 2015 Jul; 21(13):2892-7. PubMed ID: 25931451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
    Hersey P; Gowrishankar K
    Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 Blockers.
    Wolchok JD
    Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-DM1 aids patients with advanced breast cancer.
    Cancer Discov; 2013 Dec; 3(12):OF5. PubMed ID: 24327714
    [No Abstract]   [Full Text] [Related]  

  • 16. A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma.
    Alnahhas I; Wong J
    Muscle Nerve; 2017 Jun; 55(6):E25-E26. PubMed ID: 27935080
    [No Abstract]   [Full Text] [Related]  

  • 17. PD-1 inhibitor approved for melanoma.
    Cancer Discov; 2014 Nov; 4(11):1249. PubMed ID: 25367933
    [No Abstract]   [Full Text] [Related]  

  • 18. Obinutuzumab looks impressive in CLL.
    Cancer Discov; 2014 Apr; 4(4):OF5. PubMed ID: 24706674
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy for melanoma using programmed death 1 checkpoint inhibitors.
    Hamid O
    Clin Adv Hematol Oncol; 2014 Nov; 12(11):782-4. PubMed ID: 25674719
    [No Abstract]   [Full Text] [Related]  

  • 20. Trastuzumab beyond progression in advanced breast cancer: national guidance versus oncologist's decision.
    Wong HH; Collins J; McAdam K; Wilson C
    Oncology; 2014; 86(1):22-3. PubMed ID: 24335099
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.